ABVC BioPharma Inc. (ABVC)
NASDAQ: ABVCHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ABVC stock chart
Technical analysisKey statistics
All statistics- Market cap
- $23.37M
- EPS (TTM)
- -$0.20
- Dividend yield
- None
- 52-week range
- 0.707 – 2.87
- Day range
- 0.85 – 0.917
- Volume / Avg
- 39.05K / 81.92K
- Beta
- —
- Shares outstanding
- 26.98M
52-week range
ABVC stock today
ABVC BioPharma (ABVC) closed at $0.8663 on Nov 20, down 1.56% (-$0.0137), versus the S&P 500's 3.70% decline. Trading was light, with 39.05K shares changing hands, about 48% of the average daily volume. At this level, ABVC sits near the bottom of its 52-week range of $0.707 to $2.87: 69.8% below the high, set on Nov 28, 2025 and 22.5% above the low.
ABVC is down 59.3% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 67.8%. ABVC BioPharma has posted a net loss over the last twelve months (EPS of -$0.20), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About ABVC BioPharma
Company profileABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus, which is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer; ABV-2001, an intraocular irrigation solution; ABV-2002, a corneal Storage Solution; and ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Uttam Yashwant Patil Ph.D.
- Headquarters
- Fremont, CA
- Employees
- 16
- Website
- abvcpharma.com
Financial highlights
Full financialsIn fiscal 2025, ABVC BioPharma generated $296,000 in revenue, down 41.9% from fiscal 2024, its first annual decline since 2023. ABVC BioPharma reported a net loss of $7.9 million, compared with a loss of $4.9 million a year earlier. Operating margin was -2416.0%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $296.00K | $509.59K | $152.43K | $969.78K | $355.80K |
| Growth | -41.91% | +234.31% | -84.28% | +172.57% | -26.34% |
| Net income | $-7.91M | $-4.90M | $-7.79M | $-16.42M | $-12.84M |
| EPS (diluted) | $-0.39 | $-0.42 | $-1.80 | $-5.19 | $-0.51 |
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 10, 2026
- EPS actual vs est.
- $-0.04 vs —
ABVC BioPharma peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| SCYXSCYNEXIS Inc. | 2.38 | -8.64% | $23.69M | vs ABVC |
| LITSLite Strategy Inc. | 0.8026 | -4.03% | $23.99M | vs ABVC |
| IXHLIncannex Healthcare Inc. | 1.86 | +6.90% | $23.34M | vs ABVC |
| RMTIRockwell Medical Inc. | 5.82 | -7.03% | $23.12M | vs ABVC |
| IMMPImmutep Limited ADR | 3.11 | -9.06% | $22.92M | vs ABVC |
| CRVOCervoMed Inc. | 1.46 | +9.77% | $22.09M | vs ABVC |
| BCTXBriaCell Therapeutics Corp. | 3.06 | -3.32% | $26.72M | vs ABVC |
| TELOTelomir Pharmaceuticals Inc. | 0.364 | -17.24% | $26.82M | vs ABVC |
Indexes, lists and sector
ABVC BioPharma stock FAQ
What is ABVC BioPharma's stock price today?
ABVC last traded at $0.8663 as of Nov 20, 4:00 PM EST, down 1.56% on the day. Prices are delayed at least 15 minutes.
Does ABVC BioPharma pay a dividend?
No. ABVC BioPharma does not currently pay a regular cash dividend.
Who is ABVC BioPharma's CEO?
Dr. Uttam Yashwant Patil Ph.D. is the chief executive officer of ABVC BioPharma Inc., which has about 16 employees.
Has ABVC ever split its stock?
Yes. The most recent ABVC stock split was a 1-for-10 split on Jul 25, 2023, one of 6 splits on record.
What is the ABVC 52-week high?
The 52-week high for ABVC is $2.87 and the 52-week low is $0.707. The stock is currently 69.8% below its high.